ProCE Banner Activity

First-line Camrelizumab, Apatinib, and Temozolomide in Advanced Acral Melanoma

Slideset Download
Conference Coverage
A triplet combination of camrelizumab (anti–PD-1), apatinib (VEGFR-2–targeted TKI), and temozolomide showed promising antitumor activity and manageable toxicity in previously untreated advanced acral melanoma.

Released: June 13, 2022

Expiration: June 12, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab